1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Biden’s Budget Seeks To Reduce Errors In Medical Diagnoses

 
• By Brian Bossetta

US President Joe Biden’s proposed 2023 budget earmarks funds to the Agency for Healthcare Research and Quality to establish diagnostic safety centers of excellence to help cut down on medical testing errors.

Medical Mistake Test Tube
• Source: Alamy

Approximately 12 million Americans suffer a diagnostic error each year, and more than 4 million experience severe consequences because of these errors or from diagnostic delays, according to the Agency for Healthcare Research and Quality (AHRQ), which is part of the Department of Health and Human Services (HHS).

And these diagnostic errors come at a high cost to the US healthcare system – more than $100bn a year based on agency estimates.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.